SCHEMBL22602175

SCHEMBL22602175

CCOC(=O)/C(C#N)=C/Nc1ccc(OC)c(OCCCOC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.58
KDM4E B2RXH2 7/20 0.58
HPGD P15428 5/20 0.58
GAA P10253 2/20 0.58
NPSR1 Q6W5P4 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
PKM P14618 1/20 0.54
HTT P42858 1/20 0.54
DHODH Q02127 2/20 0.53
GLA P06280 1/20 0.50
MAPT P10636 6/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RXFP1 Q9HBX9 3/20 0.46
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14314065 0.89 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL4724693 0.89 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL4724694 0.89 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL29409649 0.87 DHODH (0.54) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL22589544 0.87 DHODH (0.54) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL22589464 0.87 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDGAAPKM
SCHEMBL2062533 0.84 DHODH (0.60) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL2062530 0.84 DHODH (0.60) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL20775210 0.81 NPSR1 (0.61) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL20775209 0.81 NPSR1 (0.61) ALDH1A1KDM4EHPGDGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 CN disclosed
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION 2022-09-01 US disclosed
EP-3959197-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-02 EP disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT ALDH1A1 2425/4885KDM4E 2610/4885HPGD 769/4885
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT ALDH1A1 2425/4885KDM4E 2610/4885HPGD 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.